Trial watch

Trial Watch: Monoclonal antibodies in cancer therapy

(2012) Lorenzo Galluzzi et al.   OncoImmunology

A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens

(2011) H. Pere et al.   BLOOD

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

(2011) Oliver Kepp et al.   CANCER AND METASTASIS REVIEWS

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission

(2011) Christina S. Chu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response

(2011) J. Fucikova et al.   CANCER RESEARCH

Targeting p53 to mitochondria for cancer therapy

(2011) Lorenzo Galluzzi et al.   CELL CYCLE

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

(2011) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

(2011) W. Joost Lesterhuis et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine

(2011) Craig L. Slingluff et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

(2011) R. Beverly Raney et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group

(2011) Nicolas Moosmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation ofSmad4(Dpc4)Immunostaining With Pattern of Disease Progression

(2011) Christopher H. Crane et al.   JOURNAL OF CLINICAL ONCOLOGY

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

(2011) Bernhard Mlecnik et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma

(2011) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial

(2011) Michel Ducreux et al.   LANCET ONCOLOGY

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

(2011) Frédéric Peyrade et al.   LANCET ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

(2011) M. Michaud et al.   SCIENCE

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients

(2011) Gabriela Bindea et al.   Seminars in Immunopathology

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

(2010) T. Nakahara et al.   BLOOD

The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro

(2010) Jürgen Sonnemann et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions

(2010) Mareike Schmudde et al.   CANCER LETTERS

Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death

(2010) R. Zappasodi et al.   CANCER RESEARCH

Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity

(2010) L. Aymeric et al.   CANCER RESEARCH

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

(2010) G. Schiavoni et al.   CANCER RESEARCH

Decoding Cell Death Signals in Inflammation and Immunity

(2010) Laurence Zitvogel et al.   CELL

Chemotherapy induces ATP release from tumor cells

(2010) Isabelle Martins et al.   CELL CYCLE

Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents

(2010) I. J. M. de Vries et al.   CLINICAL CANCER RESEARCH

Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer

(2010) Luis E. Raez et al.   Clinical Lung Cancer

Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study

(2010) Atul Sharma et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

(2010) Volker Moebus et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC

(2010) Tim F. Greten et al.   JOURNAL OF IMMUNOTHERAPY

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

(2010) Catriona Parker et al.   LANCET

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study

(2010) Birgit Gruenberger et al.   LANCET ONCOLOGY

Molecular mechanisms of necroptosis: an ordered cellular explosion

(2010) Peter Vandenabeele et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

(2010) I Martins et al.   ONCOGENE

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

(2010) M. P. Chao et al.   Science Translational Medicine

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

(2009) Y. Lee et al.   BLOOD

Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors

(2009) Julie L. Lucas et al.   CELLULAR IMMUNOLOGY

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death

(2009) Theocharis Panaretakis et al.   EMBO JOURNAL

Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater

(2009) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

(2009) Carola A.S. Arndt et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer

(2009) Margot Burnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

(2009) Andrew X Zhu et al.   LANCET ONCOLOGY

Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance

(2009) Michael R. Elliott et al.   NATURE

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE

Cyclophosphamide and cancer: golden anniversary

(2009) Ashkan Emadi et al.   Nature Reviews Clinical Oncology

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

(2008) D. Buglio et al.   BLOOD

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

(2008) T Panaretakis et al.   CELL DEATH AND DIFFERENTIATION

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

(2008) G Kroemer et al.   CELL DEATH AND DIFFERENTIATION

Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death

(2008) N Tajeddine et al.   ONCOGENE